We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

308 hedge funds and large institutions have $8.26B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 109 increasing their positions, 127 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $199M | Put options by funds: $81.4M

21% more capital invested

Capital invested by funds: $6.82B → $8.26B (+$1.43B)

1% more funds holding

Funds holding: 304308 (+4)

9% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 46

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

14% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 127

Holders
308
Holders Change
+4
Holders Change %
+1.32%
% of All Funds
8.85%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.26%
New
50
Increased
109
Reduced
127
Closed
46
Calls
$199M
Puts
$81.4M
Net Calls
+$117M
Net Calls Change
+$65.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$65.1M +$58.3M +527,800 New
HM
27
HealthCor Management
New York
$64.8M -$13.8M -125,000 -19%
1832 Asset Management
28
1832 Asset Management
Ontario, Canada
$64.5M +$58.2M +526,500 New
Northern Trust
29
Northern Trust
Illinois
$62.8M -$7.8M -70,571 -12%
First Trust Advisors
30
First Trust Advisors
Illinois
$60.5M -$2.95M -26,661 -5%
Goldman Sachs
31
Goldman Sachs
New York
$60.4M +$22.1M +199,997 +69%
KI
32
Kalmar Investments
Delaware
$60M +$806K +7,295 +2%
BA
33
BlackRock Advisors
Delaware
$57.1M +$50.1M +453,467 +4,622%
Charles Schwab
34
Charles Schwab
California
$56M +$29.6M +267,841 +144%
AAMU
35
Amundi Asset Management US
Massachusetts
$51.5M -$3.67M -33,177 -7%
FIM
36
Foresters Investment Management
New York
$46.9M +$133K +1,200 +0.3%
ACM
37
Apex Capital Management
Ohio
$43.8M +$14.8M +134,138 +61%
ZCI
38
Zevenbergen Capital Investments
Washington
$43.1M -$4.69M -42,410 -11%
Ninety One (UK)
39
Ninety One (UK)
United Kingdom
$41.6M +$37.3M +337,194 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$41.6M -$9.73M -88,037 -21%
Schroder Investment Management Group
41
Schroder Investment Management Group
United Kingdom
$40.8M -$5.02M -45,440 -12%
Allianz Asset Management
42
Allianz Asset Management
Germany
$40.7M +$7.72M +69,807 +27%
Geode Capital Management
43
Geode Capital Management
Massachusetts
$40M -$2.47M -22,320 -6%
RIM
44
Rainier Investment Management
Washington
$37.4M -$14.2M -128,150 -30%
TCM
45
Tang Capital Management
California
$37M
HSBC Holdings
46
HSBC Holdings
United Kingdom
$36.6M +$22M +199,152 +205%
GC
47
Guggenheim Capital
Illinois
$35.3M -$3.32M -29,994 -9%
Franklin Resources
48
Franklin Resources
California
$35M -$38.4M -347,034 -55%
GA
49
Geneva Advisors
Illinois
$33.4M -$5.94M -53,739 -17%
AAM
50
AMI Asset Management
California
$32.8M +$115K +1,043 +0.4%

SLXP Hedge Fund Activity: Q2 2014 in Review

308 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q2 2014, worth a combined $8.26B — up 21% from $6.82B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new SLXP positions and 46 closed out — a net gain of 4 holders — while 109 added to existing stakes and 127 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $148M. The largest seller was Fidelity Investments, cutting an estimated $132M.

  • 308 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q2 2014, up from 304 in Q1 2014.
  • Funds reported $8.26B of SALIX PHARMACEUTICALS LTD DEL stock for Q2 2014, up 21% quarter-over-quarter.
  • 50 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q2 2014 and 46 closed out, a net change of +4 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q2 2014 was Viking Global Investors, an estimated $148M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q2 2014 was Fidelity Investments, an estimated $132M sold.

Based on aggregated 13F filings for Q2 2014.